Moreover, we demonstrated that the risk score signature based on the screened FAM genes could distinguish the immune subtypes in patients with colon cancer, and the risk score was positively correlated with the expression of immune checkpoint molecules such as PD-1, PD-L2 and CTLA4. This evidence concerns the gene CTLA4 and colonic neoplasm.